Ignite Creation Date:
2024-05-06 @ 12:28 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03761914
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2022-02-21
First Post:
2018-11-28
Brief Title:
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sponsor:
Sellas Life Sciences Group
Organization:
Sellas Life Sciences Group
Organization Data
Organization:
Sellas Life Sciences Group
Class:
INDUSTRY
Study ID:
SLS17-201MK3475-770
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sellas Life Sciences Group
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |
| Cancer Insight LLC | INDUSTRY |